- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
What We’re Reading: AHIP President to Step Down; House Panel Advances PBM Bills; Default Could Stop FDA Reviews
AHIP president and CEO Matthew Eyles will step down later this year; the House Energy and Commerce Committee moved a series of health care measures concerning pharmacy benefit managers (PBMs); US debt default could stop FDA drug and device reviews, said FDA chief.
AHIP President and CEO to Step Down
President and CEO of America’s Health Insurance Plans (AHIP) Matthew Eyles has decided to step down from the group in October after almost 5 years at the helm, AHIP announced. During his tenure at the lobbying group, insurers overall saw growth in Medicare Advantage plans and Medicaid managed care. AHIP said it was his decision to leave.
House Panel Furthers Transparency and PBM Bills
The House Energy and Commerce Committee moved ahead a series of health care measures to elevate price transparency and reconstruct regulation of pharmacy benefit managers (PBMs) in a predominantly bipartisan markup Wednesday, reported AXIOS. The measures advanced on a unanimous 49-0 vote that addressed codifying and strengthening hospitals and insurers to make negotiated prices easier to access, imposing new transparency requirements on PBMs and forbidding their ability to charge more than they pay for a drug and keep the difference in Medicaid, and more.
US Debt Default Could Stop Drug, Device Approvals
FDA approvals of emerging drugs and devices will stop if the debt ceiling negotiations fail and the US defaults on its debt, said Commissioner Robert Califf, according to Bloomberg Law. Debt limit conversations remain at a deadlock over spending cuts, especially those demanded by Republicans. A default would mean the company has nothing to pay FDA scientific reviewers. US Treasury Secretary Janet Yellen said the government could be drained of funds by June 1.
Dr Dalia Rotstein: Physicians Must Be Aware MS Affects People of All Backgrounds
April 24th 2024Dalia Rotstein, MD, MPH, emphazises the importance of awareness that multiple sclerosis (MS) impacts patients from various backgrounds as clinicians think through ways to improve access to care and research efforts in MS.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
The Federal Trade Commission's (FTC's) vote to ban most employers from issuing and enforcing noncompete clauses could have varying impacts on the health care workforce; federal regulators vastly under-enforced antitrust laws in the hospital sector during the last 2 decades, resulting in increased health costs; the FDA recently found genetic evidence of the H5N1 bird flu virus in pasteurized commercially purchased milk.
Read More
Navigating Health Policy in an Election Year: Insights From Dr Dennis Scanlon
April 2nd 2024On this episode of Managed Care Cast, we're talking with Dennis Scanlon, PhD, the editor in chief of The American Journal of Accountable Care®, about prior authorization, price transparency, the impact of health policy on the upcoming election, and more.
Listen
What We’re Reading: Abortion Privacy Rules; Alzheimer Drug Hurdles; Nursing Home Staffing Overhaul
April 23rd 2024New health privacy rules aim to protect patients and providers in an evolving abortion landscape; some physicians express concerns about efficacy, risks, and entrenched beliefs in treating Alzheimer disease; CMS addresses longstanding staffing deficits in nursing homes.
Read More
